HCP0605 + HGP1405

HCP0605 + HGP1405 is an experimental **oral combination therapy** investigated primarily for pharmacokinetic profiling and safety in healthy volunteers[1][3][5][9]. Both HCP0605 and HGP1405 are code names for investigational agents developed by Hanmi Pharmaceutical; their exact composition, individual mechanisms of action, and therapeutic targets are currently undisclosed. The combination was administered as a loose blend—not a fixed-dose co-formulation—in completed Phase 1 clinical trials, with endpoints focused on pharmacokinetics (AUClast, Cmax, AUCinf, T1/2, Cl/F, Vz/F, Tmax)[1][3][5][9]. No specific disease indication beyond “healthy” volunteers has been stated in publicly available records. No information exists in English-language sources regarding their molecular modality, class, or underlying mechanism at this time.